Abstract
In a three-year pilot study on 52 women with severe postmenopausal osteoporosis, treatment with etidronate followed by calcium and vitamin D (ECaD) was compared to etidronate followed by monofluorophosphate, calcium and vitamin D (EFCaD). BMD in lumbar spine, total hip and femoral neck increased significantly more with EFCaD than with ECaD. Pain-mobility score decreased significantly more with EFCaD than with ECaD (p=0.006). New vertebral fractures occurred in three patients under EFCaD (12%) and in nine under ECaD (35%), (p=0.048). Three patients under EFCaD (12%) and 15 under ECaD (58%) did not respond to therapy (p of difference=0.001). Mild or moderate adverse reactions were reported by 25 patients, with no significant difference between the two groups. The pilot study suggests that etidronate, sequentially followed by monofluorophosphate, could be a safe, effective and relatively inexpensive therapy in severe postmenopausal osteoporosis.
Publication types
-
Clinical Trial
-
Comparative Study
MeSH terms
-
Absorptiometry, Photon
-
Aged
-
Bone Density / drug effects
-
Bone and Bones / diagnostic imaging
-
Bone and Bones / metabolism
-
Calcaneus / diagnostic imaging
-
Calcaneus / drug effects
-
Calcaneus / physiopathology
-
Calcium / administration & dosage*
-
Dietary Supplements
-
Drug Therapy, Combination
-
Etidronic Acid / therapeutic use*
-
Female
-
Fluorides / therapeutic use*
-
Fractures, Spontaneous / prevention & control*
-
Humans
-
Osteoporosis, Postmenopausal / metabolism
-
Osteoporosis, Postmenopausal / physiopathology
-
Osteoporosis, Postmenopausal / therapy*
-
Pain / physiopathology
-
Pain / prevention & control
-
Phosphates / therapeutic use*
-
Pilot Projects
-
Range of Motion, Articular / drug effects
-
Spinal Fractures / diagnostic imaging
-
Spinal Fractures / prevention & control
-
Treatment Outcome
-
Ultrasonography
-
Vitamin D / administration & dosage*
Substances
-
Phosphates
-
Vitamin D
-
fluorophosphate
-
Etidronic Acid
-
Fluorides
-
Calcium